Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer
NCT04786093Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by UT Southwestern Medical Center. Started Jul 2021; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04786093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786093.